Abstract 581P
Background
Although colorectal cancer (CRC) survivors often suffer from defecation related symptoms (DRS), there are very few treatment options to improve DRS. Strengthening of abdominal muscles to increase intra-abdominal pressure and pelvic floor exercises to improve pelvic floor dyssynergia may improve DRS in colorectal cancer patients. However, the effects of exercise on DRS have not been studied fully. Therefore, the purpose of this study is to investigate the efficacy of exercise on DRS in CRC.
Methods
A total of 120 CRC who completed surgery and adjuvants therapy were recruited out of 441 approached. 120 participants were randomly assigned to either exercise (EG) or usual care group (CG). The combined weekly supervised and home-based exercise program (12 weeks) includes increase in physical activity (PA) levels to meet the ACSM guideline as well as daily calisthenics exercises. Calisthenics exercises include a total of 12 movements aimed to increase whole body muscle strengths which focused on core and pelvic floor muscles. The primary outcome was DRS score assessed the sum of blood and mucus in stool, stool frequency, abdominal pain, buttock pain, bloating, flatulence, fecal incontinence and embarrassment in EOTRC-QLQ-CR29. A two-way ANOVA repeated measures were used determine group and time interaction. Table: 581P
Effects of exercise on defecatory symptoms
Control | Exercise | p-value | |||
Pre | Post | Pre | Post | ||
Blood in stool | 4.7 ± 9.7 | 4.4 ± 9.1 | 7.2 ± 15.5 | 3.1 ± 8.9 | 0.05 |
Stool frequency | 26.3 ± 27.0 | 20.1 ± 20.5 | 28.7 ± 25.1 | 23.4 ± 23.8 | 0.91 |
Abdominal pain | 14.4 ± 22.4 | 11.7 ± 19.2 | 18.3 ± 24.9 | 10.0 ± 16.6 | 0.21 |
Buttock pain | 12.2 ± 21.2 | 12.8 ± 25.4 | 18.9 ± 30.3 | 12.8 ± 26.1 | 0.08 |
Bloating | 22.8 ± 22.5 | 25.0 ± 25.8 | 34.4 ± 30.7 | 22.8 ± 27.1 | 0.01 |
Flatulence | 21.0 ± 26.0 | 17.7 ± 23.3 | 28.3 ± 33.5 | 21.5 ± 25.1 | 0.42 |
Fecal incontinence | 13.5 ± 20.5 | 13.1 ± 20.5 | 16.9 ± 24.8 | 12.9 ± 25.3 | 0.26 |
Embarrassment | 20.4 ± 26.8 | 16.7 ± 20.8 | 27.6 ± 32.0 | 18.0 ± 25.5 | 0.16 |
Bolds were statistically significant different between pre and post (p<.05), p= Difference between control vs. exercise
Results
Among the 120 participants enrolled, 100 (96.6%) completed the trial with supervised exercise compliance rate of 95%. PA levels increased and fitness levels improved only in the exercise group. Exercise significantly decreased DRS score (6 week - 0 week: CG= -14.0 ± 54.7 vs. EG= - 56.1 ± 99.5, p for group and time interaction = 0.02). Symptom scores in EG include blood and mucus in stool, abdominal pain, buttock pain, bloating, flatulence and embarrassment were improved.
Conclusions
It is concluded that both combined supervised and home-based exercise significantly reduced bowel and defecatory problems in colorectal cancer patients.
Clinical trial identification
This study was approved by The Institutional Review Board of Severance Hospital (IRB No. 4-2018-0841).
Editorial acknowledgement
This study was funded by the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (HA16C0012020020) and Yonsei Signature Research Cluster Program of 2021-22-0009.
Legal entity responsible for the study
The authors.
Funding
The National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea, Yonsei Signature Research Cluster Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
518P - Artificial intelligence real-world applications in pediatric neuro-oncology: The AICCELERATE project
Presenter: Federica D'Antonio
Session: Poster session 10
519P - The landscape of PDGFRA mutation in Chinese patients with glioma
Presenter: Qiang Lv
Session: Poster session 10
520P - Copy number variation spectrum analysis of primary glioblastoma
Presenter: Chuandong Cheng
Session: Poster session 10
521P - Deciphering a three-miRNA signature as a prognostic biomarker in glioma patients: Correlation with DFS and OS
Presenter: Ana Belen Diaz Mendez
Session: Poster session 10
522P - Galectin 3 binding protein as potential biomarker in glioma diagnosis
Presenter: Rashmi Rana
Session: Poster session 10
523P - Analysis of DNA damage response (DDR) gene expression as a prognostic factor for glioblastoma patient mortality
Presenter: Alessia-Tara Droesse
Session: Poster session 10
524P - Cell line study of nucleosome-based biomarkers in the diagnosis and detection of relapses in glioblastoma
Presenter: Jonathan Decarpentrie
Session: Poster session 10
525P - Immuno markers in newly glioblastoma patients underwent Stupp protocol after neurosurgery
Presenter: Lorena Gurrieri
Session: Poster session 10
526P - In silico evaluation of the mutational profile of glioblastomas with high expression of PD1, CTLA4 and LAG3 identifies the ERBB-PI3K pathway as a druggable vulnerability target
Presenter: Cristina Saiz-Ladera
Session: Poster session 10
527P - Targetable gene fusions and other alterations in central nervous system tumors assessed by RNA and DNA-based next-generation sequencing
Presenter: LEIMING WANG
Session: Poster session 10